XML 12 R36.htm IDEA: XBRL DOCUMENT v3.19.3
Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)
 1 Months Ended 3 Months Ended 7 Months Ended 9 Months Ended 16 Months Ended 28 Months Ended 68 Months Ended
Apr. 05, 2018
USD ($)
Sep. 30, 2019
USD ($)
May 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
milestone
May 31, 2017
USD ($)
Jan. 31, 2014
USD ($)
program
Sep. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Sep. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2019
USD ($)
Milestone
Sep. 30, 2018
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2019
USD ($)
Product
Sep. 30, 2019
USD ($)
Product
Aug. 31, 2019
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Revenues             $ 21,958,000   $ 23,562,000   $ 47,577,000 $ 57,615,000        
Other long-term liabilities   $ 5,542,000         5,542,000     $ 1,960,000 5,542,000   $ 5,542,000 $ 5,542,000 $ 5,542,000  
California Institute For Regenerative Medicine Agreement                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Funds due under the agreement     $ 8,000,000.0                          
Other long-term liabilities   5,500,000         5,500,000     1,800,000 5,500,000   5,500,000 5,500,000 5,500,000  
California Institute For Regenerative Medicine Agreement | Research Grants                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Revenues                   1,700,000     5,200,000      
Kite Pharma Inc                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Revenues             8,861,000   9,028,000   26,233,000 16,544,000        
Kite Pharma Inc | Collaboration Agreements                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Revenues             $ 6,296,000   6,296,000   18,682,000 12,249,000        
Kite Pharma Inc | Collaboration and License Agreement                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Collaboration waiting period under HSR expiration date at which time agreement became effective Apr. 05, 2018                              
Milestone payments received $ 150,000,000.0                              
Initial research term of agreement 6 years                              
Lease agreement, extendable lease term 2 years                              
Research agreement term             an option to extend the research term of the agreement for up to two additional one-year periods for a separate upfront fee of $10.0 million per year.                  
Separate upfront fee $ 10,000,000.0                              
Collaborative arrangement estimated reimbursable service costs for new research plan   3,400,000                            
Collaborative arrangement transaction price 189,300,000                              
Revenues under agreement 150,000,000.0                              
Collaborative arrangement estimated reimbursable service costs 39,300,000                              
Deferred revenue   112,800,000         $ 112,800,000     131,500,000 112,800,000   112,800,000 112,800,000 112,800,000  
Kite Pharma Inc | Collaboration and License Agreement | Maximum                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Development and sales-based milestone payments to be received 3,010,000,000.00                              
Kite Pharma Inc | Collaboration and License Agreement | Achievement of Specified Research, Clinical Development, Regulatory and First Commercial Sale Milestones                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Contingent development - and sales-based milestone payments to be received 1,260,000,000                              
Kite Pharma Inc | Collaboration and License Agreement | Achievement of Specified Sales-based Milestones if Annual Worldwide Net Sales of Licensed Products Reach Specified Levels                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Contingent development - and sales-based milestone payments to be received $ 1,750,000,000                              
Pfizer                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Milestone payments received       $ 12,000,000.0                        
Collaborative arrangement transaction price       $ 12,000,000.0 $ 70,000,000.0                      
Revenues under agreement         70,000,000.0                 0    
Deferred revenue   12,400,000         12,400,000     10,000,000.0 12,400,000   12,400,000 $ 12,400,000 12,400,000  
Number of products approved | Product                           0    
Pfizer | Collaboration Agreements                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Revenue reduction due to decrease in measure of proportional cumulative performance               $ 3,000,000.0                
Revenues             468,000   394,000   $ 1,538,000 1,470,000        
Pfizer | SB-525                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Number of milestones included in transaction price | Milestone                     0          
Pfizer | Royalty Revenues                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Revenues                           $ 0    
Pfizer | C9ORF72                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Deferred revenue   8,300,000         8,300,000     9,800,000 $ 8,300,000   8,300,000 8,300,000 $ 8,300,000  
Number of milestones included in transaction price | milestone       0                        
Pfizer | Maximum | SB-525                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Potential amount to be funded for achievement of specified commercialized and sales milestones         266,500,000                      
Milestone revenue receivable         300,000,000.0                      
Pfizer | Maximum | Other Products                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Milestone revenue receivable         175,000,000.0                      
Pfizer | Achievement of Specified Clinical Development Intellectual Property and Regulatory Milestones | Maximum                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Development and sales-based milestone payments to be received         208,500,000                      
Pfizer | Achievement of First Commercial Sale Milestones | Maximum                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Development and sales-based milestone payments to be received         $ 475,000,000.0                      
Pfizer | Achievement of Specified Preclinical Development Clinical Development and First Commercial Sale Milestones | Maximum | C9ORF72                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Development and sales-based milestone payments to be received       $ 60,000,000.0                        
Pfizer | Achievement of Commercial Milestones | Maximum | C9ORF72                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Development and sales-based milestone payments to be received       $ 90,000,000.0                        
Pfizer SB-525 | Collaboration Agreements                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Revenues             3,440,000   10,421,000   5,035,000 26,262,000        
Sanofi                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Revenues under agreement           $ 20,000,000.0                    
Number of products approved | Product                             0  
Revenues             2,754,000   2,240,000   7,763,000 11,139,000        
Number of research programs | program           2                    
Sanofi | Collaboration Agreements                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Revenues             940,000   $ 1,094,000   2,594,000 $ 3,432,000        
Sanofi | Collaboration and License Agreement                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Milestone payments received                     $ 6,000,000.0          
Collaborative arrangement transaction price           $ 75,700,000                    
Revenues under agreement           20,000,000.0                    
Collaborative arrangement estimated reimbursable service costs           55,700,000                    
Number of milestones included in transaction price | Milestone                     0          
Sanofi | Collaboration and License Agreement | Royalty Revenues                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Revenues                             $ 0  
Sanofi | Collaboration and License Agreement | Maximum                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Development and sales-based milestone payments to be received           276,300,000                    
Sanofi | Collaboration and License Agreement | Achievement Of Specified Clinical Development And Regulatory Milestones | Maximum                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Development and sales-based milestone payments to be received           115,800,000                    
Sanofi | Collaboration and License Agreement | Achievement of Specified Sales Milestones | Maximum                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Development and sales-based milestone payments to be received           $ 160,500,000                    
Sanofi | Collaboration and License Agreement                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Deferred revenue   $ 2,000,000.0         $ 2,000,000.0     $ 4,600,000 $ 2,000,000.0   $ 2,000,000.0 $ 2,000,000.0 $ 2,000,000.0  
Milestone revenue receivable                               $ 6,000,000.0